NEWS September 28, 2017

Immune’s rare skin disease drug maintains shine

Story in BioWorld by Michael Fitzhugh. Preliminary data on three additional patients enrolled in a small open-label study of Immune Pharmaceuticals Inc.’s bertilimumab, an experimental treatment for the rare blistering disease bullous pemphigoid (BP), continued to suggest it may offer an effective alternative to systemic corticosteroids, a standard but imperfect therapy for the condition. Immune, which is seeking an […]

Keep Reading

NEWS December 22, 2016

Immuno Oncology R&D Update, December 2016

Immune Pharmaceuticals is excited to share with you our latest news concerning immuno oncology. We have gathered interviews, presentations, and written material to help bring you up to speed. In December 2016, the Immune Pharma team traveled to the annual meeting of the American Society of Hematology (ASH)  in San Diego. This was an opportunity […]

Keep Reading

NEWS May 5, 2016

Delving Deep into Immune Pharmaceuticals’ Diverse Pipeline

Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on the treatment of immuno-inflammatory diseases and cancer. The company has several active clinical programs, led by bertilimumab, a first-in-class, fully human IgG4 monoclonal antibody, which is currently in Phase 2 clinical trials for the treatment of inflammatory bowel disease and skin disorders. Immune Pharma also […]

Keep Reading

NEWS April 21, 2016

Immune Presents Biomarker Data On Ceplene at AACR

A team of researchers from Gothenburg University in Sweden presented data from a Phase 4 study on Ceplene® earlier this week at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, LA. These data could have a profound impact on future use of the drug in elderly patients with Acute Myeloid Leukemia (AML). […]

Keep Reading